Scientific Program

Conference Series Ltd invites all the participants across the globe to attend International Conference on Diabetes and its Complications Osaka, Japan.

Day 2 :

Keynote Forum

Eda Cengiz

Yale School of Medicine, USA

Keynote: New Era in Diabetes Management: Artificial Pancreas Systems and Beyond

Time : 09:30 - 10:00

Conference Series  Diabetic Complications 2018 International Conference Keynote Speaker Eda Cengiz photo
Biography:

 
Dr. Cengiz is an associate professor at Yale School of Medicine, division of Pediatric Endocrinology and a visiting professor at KOC School of Medicine. She has carried out various diabetes-related clinical studies focusing on insulin action (pharmacokinetics and pharmacodynamics), diabetes technology (continuous glucose sensors and insulin pumps), and artificial pancreas (closed-loop) systems in people with T1D as a principal investigator or co-investigator. She has conducted clinical studies in collaboration with investigators from centers of excellence in diabetes care in the US and overseas and published various papers. Dr. Cengiz has been a reviewer and editorial board member of many scientific journals and meetings. She is the co-chair of the pharmacology sub-group of the National Institutes of Health Pediatric Diabetes Treatment Core Group. Dr. Cengiz collaborates with pediatric diabetologists overseas through national and international organizations to promote the well-being of children with diabetes globally.
 

Abstract:

 
 The incorporation of new technology into diabetes treatment provided diabetologists with additional tools like glucose sensors, smart insulin pumps, and the promise of closed loop insulin therapy (a.k.a the artificial pancreas project), a mechanical solution for diabetes management to restore near-physiologic glycemic control automatically. Such a system consists of three main elements: insulin delivery, continuous glucose sensing, and a controller or algorithm that, similar to the beta cell, regulates the proper amount of insulin delivery at the proper time. Advances in newer insulin formulations with improved pharmacokinetics (PK) and pharmacodynamics (PD) will galvanize closed loop insulin therapy systems and overcome challenges, such as late action of rapid acting insulins resulting in postprandial hyperglycemia. The Yale Pediatric Diabetes Center has been one of the main hubs of the artificial pancreas project and of research studies investigating the PK-PD of new insulin formulations. This talk will highlight the results of key studies in the field of diabetes technology including euglycemic clamp studies investigating the PK-PD of novel ultra fast acting insulins, the impact of innovative insulin delivery devices on insulin action, and the artificial pancreas project. It will discuss the barriers and limitations of this relatively nascent technology and solutions to overcome these challenges
 

Keynote Forum

Hsinlin Cheng

Harvard Medical School, USA

Keynote: Molecular Mechanisms of Diabetic Neuropathy: From Clinical Practice to Bench Studies

Time : 10:00 - 10:30

Conference Series  Diabetic Complications 2018 International Conference Keynote Speaker Hsinlin Cheng photo
Biography:

Dr. Hsinlin Thomas Cheng MD, PhD is the Director of Headache and Neuropathic Pain Unit, Massachusetts General Hospital and Assistant Professor of Harvard Medical School. He is board-certified in Neurology and Pain Management. His research interests include studying the molecular mechanisms of headache and neuropathic pain to establish new therapeutic equipments.

Abstract:

Diabetic neuropathy (DN) is one of the most prevalent complication from type 2 diabetes.  Up to 26 % of patients with diabetic neuropathy from type 2 diabetes report a significantly decreased quality of life caused by painful diabetic neuropathy (PDN).  The development of mechanism-specific treatments for PDN is in an urgent need. To determine the molecular mechanisms that mediate the development of PDN in patients with type 2 diabetes.  We collected skin biopsies from patients with PDN and performed novel biomarkers studies to examine intraepidermal nerve fibers (IENF).  Our results demonstrated increased biomarkers of neural regeneration (GAP43) and degeneration (axonal swelling) in patients with PDN compared to DN patients have no neuropathic pain.
To further establish the molecular signaling pathways that contribute to PDN, we used db/db mouse as a mouse model.  We examined the gene and protein expression of dorsal root ganglion neurons and concluded that nerve growth factor/Trk A/p38 signaling pathway is essential for the development of PDN in db/db mice.  This activation of this pathway leads to increased nociceptive nerve regeneration and proinflammatory cytokine-mediated inflammation in IENF.  We also detected reduced expression of interleukin (IL)-10, an anti-inflammatory cytokine during the period of PDN in db/db mice.  Exogenous IL-10 treatment significantly inhibited upregulation of, NGF, TNF-α, and reduced PDN in db/db mice.  In addition, the activation of Langerhans cells, the dendritic cells in the skin, during the period of PDN was reduced by IL-10 treatment in the hind paws of db/db mice. Our studies demonstrated the dysregulation of NGF-dependent cytokine-mediated inflammation contributes to the development PDN in type 2 diabetes.  Our results will lead to new therapies that target this pathway for treating PDN of type 2 diabetes.
 
 

Keynote Forum

Ciddi Veeresham

Kakatiya University, India

Keynote: Medicinal plants used for the management of diabetic complications

Time : 11:00 - 11:30

Conference Series  Diabetic Complications 2018 International Conference Keynote Speaker Ciddi Veeresham photo
Biography:

Ciddi Veeresham has completed his PhD at the age of  32 years from kakatiya university and postdoctoral studies from Cornell University, school of Biochemical engineering ithaca, NY USA. He is the Professor of Pharmacy at University college of Pharmaceutical Sciences, Kakatiya University, Warangal, India.. He has published more than 130 papers in reputed journals and has been serving as an editorial board member of repute.            

 

Abstract:

The inhibitory activities of extracts containing various classes of phytoconstituents such as terpenoid, phenolic and other miscellenious were studied. In vitro rat lens aldose reductase (RLAR) and rat kidney aldose reductase (RKAR) inhibitory activity of standardized extracts of Boswellia serrata (leaves), Lagerstroema. speciosa (leaves), Ocimum gratissimum (leaves), Syzygium cumin (fruits), Morus alba (leaves), Phyllanthus amarus (whole plant), Punia granatum (fruits) and Stevia rebaudiana (leaves), Cassia auriculata (flower), Saraca asoca (flower) Andrographis paniculata (aerial parts), Butea monosperma, Picrorhiza kurroa and Hibiscus rosa-sinensis at concentrations of 10, 50 and 100 µg/ml;  and their active constituents  boswellic acid, corosolic acid, ursolic acid, ellagic acid, morusin, phyllanthin, punicalagin and stevioside, procyanidin B1, leucocyanidin, andrographolide, butein, resveratrol and quercetin, each at concentrations of 1, 5 and 10 µg/ml were assayed spectrophotometrically. Among the tested extracts and compounds, standardized extract of O. gratissimum showed the highest activity, while the extract of P. kurroa and Hibiscus rosa-sinensis were the least active.
 
Among the tested pure compounds the RLAR inhibitory activity of corosolic acid, boswellic acid, ursolic acid and resveratrol were better than the rest. The above compounds with the potent inhibitory activity against RLAR were tested against human recombinant aldose reductase followed by the in vivo AR inhibitory activity in rats using galactosemic model by estimating the lens galactitol levels by using gas liquid chromatography.
Based on the above studies on the AR inhibitory activity, some of the potent compounds such as ursolic acid and resveratrol were studied for their effect on diabetic complications such as cataract and nephropathy. The compounds were tested for the in vitro anticataract activity in isolated cattle lens using organ culture technique in Krebs’ ringer buffer medium. The ability of the compounds to inhibit the glucose mediated induction of cataract was measured with respect to extent of opacity and formation of polyols in the lens.
Further to the above studies, resveratrol and ursolic acid were tested for their activity in diabetic nephropathy along with various biochemical parameters to elucidate the mechanism of action of the compounds.Thus an extensive research on various phytoconstituents for their potential in alleviating diabetic complications was carried out which might fulfill the unmet clinical need in the treatment of these complications.
 
 

Keynote Forum

Lorna Kwai Ping Suen

The Hong Kong Polytechnic University, Hong Kong

Keynote: Association of auricular reflective points and status of type 2 diabetes mellitus
Conference Series  Diabetic Complications 2018 International Conference Keynote Speaker Lorna Kwai Ping Suen photo
Biography:

Lorna Suen is an Associate Professor at the School of Nursing and the Director of the Squina International Centre for Infection Control. Her research interests include complementary and alternative medicine, sleep studies as well as infection control. She has published 90 scientific articles in international refereed journals, over 60 conference abstracts, and four book chapters. She has extensive experience in conducting randomized controlled trials using auriculotherapy in the clinical treatment of a number of chronic problems, including insomnia, low back pain, osteoarthritic knee, and uncontrolled hypertension. She is also interested in investigating the predictive value of auricular diagnosis and has recently completed several projects on identifying the relationship of auricular reflective points with the coronary heart disease, diabetes mellitus, lower urinary tract syndrome, and metabolic syndrome. She is the editorial board member of a number of international refereed journals and is frequently invited as a speaker at universities and international conferences and as a consultant in numerous non-profit organizations in Hong Kong.

Abstract:

The reflexive property of the ear can cause various physical attributes to appear on the auricle in the presence of bodily disorders. The association of auricular signals (presence or absence of discoloration, marks after pressing, tenderness, and electrical resistance) and diabetes mellitus (DM) should be further examined because auricular diagnosis is an objective, painless, and non-invasive method that provides rapid access to information. A matched case–control study on 282 subjects was conducted. Cases (n = 141) were defined as those diagnosed with type 2 DM (T2DM). Every subject in the case group was matched with the control by age and gender. Ear diagnosis was conducted by visual inspection, electrical conductivity, and tenderness testing. Results suggest that the tenderness and electrical conductivity of some auricular points, including “pancreas & gallbladder” “endocrine,” “kidney,” “lower tragus,” “heart,” and “eyes”, were associated with T2DM status in Chinese population. In the subgroup analyses, certain auricular signals were also associated with glycemic control, disease duration, and related complications. Auricular diagnosis could be considered as a screening method for vulnerable populations with T2DM risk. Thus, appropriate interventions can be implemented to prevent or delay the progression of T2DM.
 

  • Track 1: Diabetes, Types and Symptoms
    Track 4: Diabetes Chronic Complications
    Track 5: Advanced Technologies & Treatments for Diabetes
    Track 6: Metabolic Syndrome
    Track 10: Current challenges in new therapies to diabetes complications
    Track 14: Epidemiology and Public Health
Speaker
Biography:

Yong-Fu Xiao Head of pharmacology at Crown Bioscience, Inc. and adjunct professor of Rutgers University. He has extensive experiences in cardiovascular and metabolic research. Before joining CrownBio, he was principal scientist and worked on gene and protein therapy for heart and metabolic diseases in Medtronic. Before Medtronic, his work focused on cardiovascular physiology and pharmacology and was Assistant Professor of medicine, Harvard University and Associate Biophysicist at Massachusetts General Hospital. He published over 110 peer-reviewed papers, reviews, book chapters and granted over 6 patents.
 Yi-Xin (Jim) Wang senior vice president, Crown Bioscience Inc. Academia in physiology and pharmacology: postdoctoral fellow (Boston University) and assistant professor (Univesity of Tennessee at Memphis). Over 20 years working experience in major pharmaceutical companies (GSK, Roche, Schering/Bayer AG) and biotechnology Inc. (Arete) from preclinical R&D to Phase II. Specialized in cardiometabolic research with ~100 peer-reviewed publications.
 

 

Abstract:

Obesity can lead to insulin resistant and Type 2 diabetes mellitus (T2DM). Both obesity and diabetes are serious epidemic issues in developed and some developing countries. T2DM and obesity often complicate each other and escalate patients’ other healthiness. Cardiac, hepatic and renal complications of diabetes and obesity have widely been reported and studied for decades. However, the underlying mechanisms and interactions between obesity and diabetes have yet to be elucidated further. Nonhuman primates (NHPs) can spontaneously develop obesity and diabetes which are the highly valuable models for research to delineate molecular and cellular mechanisms of their pathophysiology. In our housed dysglycemic and dyslipidemic cynomolgus monkeys we evaluated cardiac, hepatic and renal complications. Echocardiography in diabetic NHPs showed left ventricular systolic and diastolic dysfunctions accompanied with left atrial hypertrophic remodeling, the phenotypes similarly to those found in diabetic patients. In addition, dyslipidemic and diabetic monkeys can develop nonalcoholic fatty liver disease (NAFLD)/steatohepatitis (NASH) assembling to the human liver disease. We also evaluated diabetic nephropathy and its molecular mechanisms in diabetic NHPs with significantly high albuminuria. Transcriptome analysis of kidney biopsies showed differentially expressed genes (DEGs) with 75DEGs related to diabetic nephropathy, but only 1 nephropathy specific gene (LCT lactase) and 4 other DEGs were highly altered in diabetic monkeys with albuminuria. Signaling pathway analysis of the relevant DEGs and encoded proteins highlighted the role of a kidney failure, renal and urological diseases, and inflammatory diseases related network, in which the most pivotal gene in this network is Tumor Necrosis Factor, indicating that nephropathy is a disease closely related to inflammation and cell death.  Therefore, noninvasive echocardiography and quantitative biomarker measurements in NHP models can be powerful translational tools for evaluation of obesity and diabetes complications and for investigation of potential novel therapies due to the pathophysiological similarity between NHP and humans.
 

 

Speaker
Biography:

Dragan Nikolic M has his expertise in research of the Diabetes, insulin secretion, transplantation, pancreatic islets culture and influence of microorganisms on the onset of the diabetes, pancreatic infection and on pancreatic islets insulin secretion. Dr. Nikolic has presented new data that could be important factors in pathogenesis of diabetes. It was established that certain bacteria and fungi could penetrate the pancreas thus directly affecting insulin secretion, or indirectly, by secreting certain metabolites which via blood get into pancreas, leading to insulin resistance and glucose intolerance, and finally to obesity and diabetes. He introduced new terms in microbiome research (Homeostatic microbiome, Ring of life). These findings will be important for the future prevention and monitoring of the patients with high risk for developing diabetes. Dr Nikolic is author of many scientific papers dealing with Diabetes and he is  Editorial board member and reviewer for many international scientific journals.

Abstract:

The aetiopathology of diabetes mellitus is not fully understood. Recent studies have confirmed that microorganisms can influence insulin secretion directly when present in the pancreas and indirectly by increasing their number in the gastrointestinal tract.  In a healthy body, microorganisms are part of the homeostatic microbiome and play a key role in maintaining health, digestion and metabolism. Formation of the Homeostatic Microbiome (Ring of Life) takes place in several stages: pregnancy and childbirth, breastfeeding, contact with family and wider environment, nutrition and sexual contacts. Many internal and environmental factors can lead to disorders of homeostatic microbiome, which leads to certain diseases, including disorder of glucose homeostasis. The present research tests the hypothesis that disruption of the homeostatic microbiome plays an important role in aetiopathogenesis of diabetes mellitus and obesity.
Our research results demonstrated that microorganism can influence on pancreatic islets insulin secretion. Namely, they perform their impact directly (when present in pancreas) and indirectly, by secreting their metabolites which have influence on pancreas islets trough the blood vessels, as a consequence of increase in their number in human body, disorder of HM emerged.
Bacterial agents (Enterobacter spp, Pseudomonas aeruginosa, Staphyloccocus spp) reduce insulin secretion leading to postprandial hyperglycemia.Fungal agents (Candida albicans) increase insulin secretion causing postprandial hypoglycemia and insulin resistance. It is known that increased insulin secretion is frequent in obese persons.Both cases lead to glucose intolerance and insulin resistance and in some cases the development of the type 2 diabetes mellitus and obesity.
 
 
 

Speaker
Biography:

Hiroshi Bando is an unique doctor with 4 main specialties. 
1) Physician: specialties are diabetes, primary care medicine, life style-related disease, with the president of Annual Congress of 8th Japanese Primary Care Association (May 2017, Takamatsu Japan, 4700 attendees).  
2) Pianist: silver award in 3rd European International Piano Concours in Japan (2012) and registered music therapist, with the president of Annual Congress of 9th Japanese Music Therapy Association (2009),
3) Athlete: speedskater in Japan National Sports Festival (1999-2003), continuing masters’ runner and lecturer in athletics.
4)Essayist: writing books 30<, printed matters 1800<, medical publication and presentation lots, the editors of several medical journals.
 
 

Abstract:

Statement of the Problem: There are lots of patients with diabetes and metabolic syndrome worldwide, and nutritional therapy is indispensable. Discussion has continued concerning Calorie Restriction (CR) and Low Carbohydrate Diet (LCD) for years. We have treated thousands of patients with type 2 diabetes mellitus (T2DM) for LCD and investigated clinical research, including ketone bodies and Morbus (M) value.
Methodology & Theoretical Orientation: Subjects were 121 patients with type 2 diabetes mellitus (T2DM), and provided Calorie restriction (CR) on day 1,2 and Low Carbohydrate Diet (LCD) from 3 to 14 days. Basal biomarkers and daily glucose profile on day 2,4 were measured.
Findings: Subjects were classified into 4 groups due to average glucose, with mean HbA1c 6.3%, 6.9%, 7.9%, 9.2%, respectively. Average glucose from day 2 to 4 in each group was significantly decreased. M value considerably decreased in group 2,3,4, indicating useful M value. As for lipids, Triglyceride from day 2 to 14 decreased considerably. RLP-C levels showed significant correlation with Triglyceride, LDL-C, atherogenic index (T-C–HDL/HDL) and TG/HDL value.
Conclusion & Significance: These results would suggest that RLP-C may be involved in the development of arteriosclerosis of T2DM, and may have the role of further research direction in the future. Further Medical Care: Associated with mentioned above, the author have continued several treatment and care for Integrative Medicine (IM) and Complementary and Alternative Medicine (CAM), such as physiotherapy, music therapy with my piano playing. I will show various trials for patient-oriented practice of medicine in the key note lecture.
 
 

Speaker
Biography:

Vivek Kamath founder of heal the world organization is a Reiki Master, Mexican Healer, Melchizedek Healer, Crystal Healer and Past Life Regression Therapy Expert. He has healed many diabetic patients (Type1, Type2, Type 3/1.5/LADA) without any medicines. He has also healed blood pressure (both high and low blood pressure), heart disease (removed the heart blockages), removed kidney stones, ovarian cysts, fibrosis of the breast, fatty liver, lungs disease, cured sinusitis, sever joint pain, lumbar L5 spinal disk pain, neck pain, constipation, rheumatoid arthritis, glaucoma, migraines, headaches, insomnia, stomach related problem, IBS, diabetic gum problems, skin problems( dry skin, eczema) and chronic nasal allergies, nasal blockages without any medicines. Some of the above treatments have been completed within a week to maximum 1month duration.  
 

Abstract:

Statement of the Problem: Diabetes Type1, Type 2 and Type 3 complications.
As most of us are aware Type 2 diabetes can be controlled and cured completely with the diet, workouts (yoga), effective stress management and other healing methods. However, Type 1 and Type 1.5/3/LADA diabetes healing or complete cure is a big challenge because of our body’s immune system issue.
With type 1/1.5 diabetes, the body’s immune system attacks part of its own pancreas. Scientists are not sure why. But our immune system mistakenly sees the insulin-producing cells in the pancreas as foreign, and destroys them. This attack is considered as "autoimmune" disease. These pancreatic cells – called “islets” are the ones that sense glucose in the blood and, in response, produce the necessary amount of insulin to normalize blood sugars.
How do we protect that these “Islets” and how can we ensure that these cells produce enough insulin hormones? Using Reiki Distant Healing and telepathy techniques I have reduced 2 patients glucose level. One was type1 case of a nine-year-old boy with high fasting glucose level (350 mg/dL) and a very high random glucose level (450 to 500 mg/dL) despite of taking high dosage insulin on daily basis for nearly 2 years it was not going down. With the reiki healing techniques, it has come down to normal level within a month or so. The same experiment repeated recently on another young gentleman 38 years old patient who was suffering from Type 1.5/3/LADA disease. His FB glucose level was around 350 to 400 mg/DL from the last 8 years despite of taking strong dose of insulin on daily basis; glucose level was not going down. Within a month after initialing Reiki healing treatment, his FB glucose level came down to 190 mg/DL.  He is showing recovery from diabetes. The conclusion from our healing study are that these healing and cure works mainly on 1 ) Energy level of the healer 2) Belief in self for the patients 3) Belief in Reiki Channel and universal energy 4) Intention and thought process/brain wave  frequency in alpha state matching between healer and patients. If all of these things are perfect, any disease can be healed. We have made an initial breakthrough in terms of reducing their glucose level. The above study has been followed on other healing such as Lumbar L5 Spine disk pain healing. It worked amazingly and patient has shown drastic improvement in their pain relief. 80% relief on pain has been felt. We are continuing with our research on this healing for various other chronic disease cure not only type1/3 diabetes.
 

Speaker
Biography:

Dr. Ibrahim El- Bayoumy  holds bachelor of medicine and surgery (Tanta faculty of medicine-Egypt,1989),then he earned his master degree in public health, preventive and social medicine (Tanta faculty of medicine-Egypt1996),and MD, PhD in public health ,preventive and social medicine 2003 from Tanta faculty of medicine-Egypt and McGill faculty of medicine –Montreal -Canada in division of clinical epidemiology in Royal Victoria hospital  through double channel system as scholarship from ministry of education-Egypt. He is full professor of public health and community medicine in Tanta faculty of medicine-Egypt. Now he is working in ministry of health in Kuwait as consultant of public health and preventive medicine.
Dr. El Bayoumy has published many research works in international journals, he is interested in research in epidemiology of infectious diseases like HIV, tuberculosis, brucellosis and infectious hepatitis, he is interested in epidemiology of chronic diseases like diabetes mellitus and its health economics and pharmacoepidemiology. He is a reviewer of many national and international journals. He has great interest also in childhood obesity and has written a chapter on childhood obesity in a book published by Nova publishers in USA.
 

 

Abstract:

 
Diabetes mellitus type 2 is characterized by gradual decrease in insulin sensitivity in the peripheral tissues and liver(insulin resistance),followed by gradual decline in Beta cell function and insulin secretion. Thus patients with poor glycaemic control require the use of insulin therapy to achieve the target of American Diabetes Association, recommending HbA1c  to be less than7%.≥ 8% despite of optimal doses of anti-diabetic drugs
This study aimed to evaluate and addressing the barriers for use of insulin in type 2 diabetes mellitus patients ,where their glycaemic control is poor i.e. HbA1c is .≥ 8% despite of optimal doses of anti-diabetic drugs.
We surveyed 200 patients with type 2 diabetes mellitus i.e. cross sectional quantitative study, patients showed poor glycaemic control HbA1c ≥ 8%,already treated with one or more oral agents, who recently prescribed insulin to control their  metabolic status . Data were obtained by patient’s interview using a validated questionnaire The place of the study was in diabetes mellitus clinic in Farwaniyah primary health care center in Kuwait
 
Patients with type 2 diabetes failing to initiate the prescribed insulin therapy have reported misconception regarding fear of hypoglycaemia  in 49% of the total sample ,pain from injections in 68% ,and self blame about need for insulin i.e. sense  of failure in 61% of total sample of study. Other factors were addressed like sensation by getting more severity of the disease, weight gain fear and other negative self perceptions and attitudinal barriers were studied.
Reducing the negative influence of psychological insulin resistance (PIR) on treatment outcomes should be a clinical priority. Approaching and understanding the multifaceted and complex nature of PIR and discussing the etiology of every patient's PIR is the first important step. The incorporation of well-validated clinical measures assessing these barriers, as well as further research should be conducted on the impact of interventions to overcome such barriers. Clinicians should prescribe simple insulin regimen to decrease their patients' fear from dependency of insulin, and the use of modern insulin analogs and insulin pen services, may greatly reduce PIR by mitigating the fear of life style changes and side effects, as well as social stigma associated with using insulin in a vial and syringe
 

 

  • Track 2: Complications in Diabetes
    Track 3: Trends in Diabetic Complications
    Track 7:Genetics of Diabetes
    Track 9: Diabetes Nursing
    Track 12: Antibiotics for Diabetes
Speaker
Biography:

Seiho Nagafuchi has graduated from Medical School of Kyushu University, Japan. He was the Resident in Department of Medicine, Kyushu University Hospital (1975) and the Visiting Fellow (1978) National Institute of Health, USA. He was the Chief Internist, Internal Medicine, Fukuoka-Teishin Hospital (1983). He was the Associate Professor (1998), Department of Health Sciences, Kyushu University; presently, a Visiting Research Scientist, Department of Hepatology, Faculty of Medicine, Saga University and a Professor Emeritus, Kyushu University, Japan since 2016.
 
 

Abstract:

Explosive increase of patients with diabetes in the world must be, at least in part, due to environmental factors, especially viruses. Experimental evidence had shown that even diabetogenic encephalomyocarditis strain D (EMC-D) virus-induced diabetes is inducible only in limited strains of mice such as SJL, DBA/2 and SWR backgrounds. We could show that natural mutation of Tyrosine kinase 2 (Tyk2) gene: Interferon (IFN) receptor-associated signaling molecule is responsible for susceptibility to murine EMC-D virus-induced diabetes, with deteriorated IFN dependent anti-viral response in pancreatic beta-cells. Moreover, a human Tyk2 gene haplotype with multiple genetic polymorphisms at promoter region in complete linkage disequilibrium, named Tyk2 promoter variant (NCBI ClinVar, variation ID: 440728), is associated with an increased risk for type-1 diabetes (T1D), particularly for anti-glutamic acid decarboxylase antibody (GADAb) negative T1D associated with flu-like syndrome at onset (Odds ratio: 3.6). Surprisingly, the risk is high in non-obese patients with type-2 diabetes (T2D) (Odds ratio: 2.4). We also found that patients with T1D had increased serum IgE levels, however, those with flu-like syndrome at the onset showed no relation to increased IgE nor anti-GAD, but with Tyk2 promoter variant. These experimental and clinical evidences taken together indicated that Tyk2 gene serves a virus-induced diabetes susceptibility gene, common to mice and humans. Conversely, these findings suggested that latent diabetogenic viruses may induce diabetes only in small fraction of people possessing virus-induced susceptibility gene. Moreover, the concept could extend to other infectious diseases such as Zika virus infection complicated with microcephalic infants among a few pregnant women. Thus, these observations should enhance the research for the identification of latently diabetogenic viruses using rodents with multiple virus-induced diabetes susceptibility genes in high sensitivity. Those studies will convincingly lead to the development of anti-diabetogenic virus vaccine not only to prevent T1D but also to reduce the risk of T2D, among patients due to viral infection.
 
 

Joseph F. Ndisang

University of Saskatchewan College of Medicine, Canada

Title: Heme oxygenase ameliorates cardio-renal complications in diabetic animals
Speaker
Biography:

Dr. Joseph Fomusi Ndisang is an Associate Professor in the University of Saskatchewan College of Medicine, Department of Physiology. He received postdoctoral training in Physiology at the University of Saskatchewan College of Medicine from 2000-2005. He obtained a PhD in Pharmacology & Toxicology from the University of Florence, Italy, 2000. He obtained a Doctor of Pharmacy degree from University of Florence, Italy in 1995. He has received several distinguished awards and distinctions including: (i) Fellow of the Canadian Cardiovascular Society (FCCS) in 2016, (ii) Fellow of the American Heart Association (FAHA) in 2011; (iii) Fellow of the International College of Angiology (FICA) in 2007; (iv) Young Investigator Award by International College of Angiology (2007); (v) Young Investigator Award by the American Society of Pharmacology & Experimental Therapeutics-Division for Drug Discovery, Development & Regulatory Affairs (2005); (vi) Young Investigator Award by the Society of Experimental Biology and Medicine (2005); (vii) Caroline tum Suden/Frances A Hellebrandt Professional Opportunity Award for Meritorious Research by the American Physiological Society (2005); and (viii) Recognition Award for Meritorious Research by a Young Investigator by the American Physiological Society (2004). Top 5% of cited authors in journals of Biology and Biochemistry in 2011, by Thomson-Reuters. Currently, Dr. Ndisang is an Editor for Frontiers in Bioscience (impact factor 3.8) and Executive Guest Editor for Current Medicinal Chemistry (impact factor 3.7) He has published more than 64-full length manuscripts in peerreviewed journals and more than 80 abstracts. Dr. Ndisang has served as external PhD examiner for several universities in Canada, has given more than 30-invited talks, and has also served as peer-reviewer for several reputed journals and granting agencies in United States, United Kingdom, Canada, New Zealand and Poland. Research Interest: His research is mainly focused on investigating the role of the heme oxygenase system in hypertension, diabetes (types-1 and -2), and obesity.
 

Abstract:

Impaired glucose metabolism and dysfunctional insulin signaling are forerunners of cardio-renal complications. Upregulating heme-oxygenase (HO) with HO-inducers potentiates insulin signaling and improved glucose metabolism in type-1 and type-2 diabetic models. Particularly, pro-inflammatory/oxidative mediators including: (i) cytokines (TNF-α, IL-6, IL-1β), (ii) chemokines (MCP-1, MIP-1α), (iii) macrophage-M1 infiltration, (iv) NF-κB, AP-1, AP-2, cJNk and 8-isoprostane were suppressed by the HO-inducer, hemin whereas components of insulinsignaling such as IRS-1, GLUT4, PI3K and PKB were robustly enhanced. Furthermore, hemin reduced insulin/glucose intolerance. These were associated with the amelioration of cardiac lesions (hypertrophy, collagen deposition in cardiomyocytes and left ventricular longitudinal muscle-fiber thickness) and the improvement of renal lesions (glomerulosclerosis, tubular necrosis, tubular vacuolization, interstitial macrophage infiltration). In addition, the HO-inducer, hemin and abrogated pro-fibrotic/extracellular-matrix proteins like collagen and fibronectin that deplete nephrin, a protein which forms the scaffolding of the podocyte slit-diaphragm for filtration. Correspondingly, improved cardiac hemodynamics and reduced albuminuria/proteinuria and enhanced creatinine clearance was observed suggesting improved cardiac and renal functions. Collectively, these data suggest that HO-inducers may be explored in the search for novel and effective remedies against cardio-renal complications.
 

Speaker
Biography:

Achaiah Garlapati has been working as Professor at Pharmacy institute in Kakatiya university and associated with design, synthesis and screening of various heterocyclic compounds for different biological potencies viz anticancer, anti-inflammatory, antihistaminic, antidiabetic and antimicrobial activities. He guided several PhD students and project work as number of post-graduate students. Some of the compounds synthesized were found to more potent than the existing drug molecules. The results are published in several peer reviewed journals.

 

Abstract:

1,3-Thiazolidindiones (TZDs) are important class of antidiabetic agents which enhance insulin sensitivity of the target cells via activation of  Peroxisome Proliferator-Activated Receptor gamma (PPAR-γ), a nuclear receptor involved primarily in glucose homeostasis, adipogenesis, inflammatory diseases and certain types of cancers.1,3-Thiazolidindiones are associated with  various untoward effects, restricting their usage in the treatment of Type 2 diabetes. The main side effects of all TZDs are water retention, heart failure. Therefore, TZDs should be prescribed with both caution and patient warnings about the potential for water retention/weight gain, especially in patients with decreased ventricular function. The two TZDs, pioglitazone and rosiglitazone, are PPAR-γ agonists, do not cause serious liver damage, but do induce weight gain, fluid retention and heart failure and they have been associated with an increase in peripheral fractures in postmenopausal women, particularly in the humerus, hands and feet. Furthermore, it has been established that selective activation of PPAR-γ sub-type is primarily responsible for the observed undesirable effects. Therefore, partial agonists are considered a safer alternative to currently used thiazolidinediones (TZDs).
 
The attempt to develop such molecules, several modifications have been attempted in the tail and head groups of the TZDs to result in thiazolidin-4-ones and a few of them have been identified to possess potential antihyperglycemic activity.  The purpose of this study is to synthesize and screen new derivatives (General Structure) obtained by the incorporation of pyridine/pyrimidine in the tail and thiazolidine-4-one with cyclopropyl, alkyl, aryl groups etc. In place of R group and methyl and hydrogen in place of R1. Methodology: 4-[2-(Methyl-pyrimidin/pyridin-2-yl-amino)-ethoxy]-benzaldehyde (2) was prepared from 2-(methyl-pyrimidin/pyridin-2-yl-amino)-ethanol (1) and 4-fluorobenzaldehyde. The compound 2 in turn treated with appropriate amine and thioglycolic acid/ thiolactic acid to get the thiazolidine-4-ones. Findings: All the seven target molecules showed significant reduction in blood glucose levels in the streptozotocin induced diabetic rats at 4th and 6th Hrs after administration. Among the series, the compound with cyclopropyl group and pyridine moiety (IIg) showed comparable potency to that of the standard piogliazone at 6th hour (~55% reduction). Further, the activity increased with % reduction in blood glucose levels reaching 65.75 at 10th Hrs compared to 3% shown by standard indicating prolonged activity by the test compound.  Conclusion & Significance: The findings suggest that compound (IIg) could be further modified to improve the potency and tested for toxicity to identify safer molecules for further pre-clinical evaluation.
 

Speaker
Biography:

Xiaochun Liang is Director and Doctorate tutor of the Department of TCM in Peking Union Medical College Hospital. She is engaged in the study of diabetes and its complications and developed Jinmaitong capsule for the treatment of diabetic peripheral neuropathy. Prof. Liang presides over 18 scientific research projects such as the National Natural Science Foundation of China and published more than 200 papers. Furthermore, she has written or edited more than 20 academic books. Prof. Liang was awarded 11 scientific research awards such as Beijing Scientific and Technological Progress. Besides, she was entitled “Beijing 2nd Award of General Higher School Achievement” for her outstanding contribution to the reform of TCM teaching. She is a member of the academic committee of the Chinese Academy of Medical Sciences and the executive director of the China Society of Integrated Traditional Chinese and Western medicine.

 

Abstract:

Statement of the Problem: Up to 50% of patients with diabetes mellitus develop peripheral neuropathy. Painful peripheral neuropathy has a profound negative impact on quality of life and is one of the leading causes of non-traumatic lower limb amputations. The pathogenesis of diabetic peripheral neuropathy (DPN) remains unclear and there are no drugs known to halt or reverse the progression of DPN. The purpose of this study is to  seek effective methods for the treatment of DPN from the traditional Chinese Medicine. Methodology & Theoretical Orientation: Guided by the thought of integrated traditional and western medicine, a long term study on the etiology, pathogenesis and syndrome characteristics of DPN is carried out. Then we developed the compound traditional Chinese medicine Jinmaitong capsule, and its clinical efficacy was verified. Findings: The syndrome of Yin-Yang deficiency with blood stasis is the most common syndrome differentiation type of DPN. The scores of neurological symptoms and signs were positively correlated with the scores of yin deficiency, Yang deficiency and blood stasis. The more severe Yang deficiency and blood stasis, the slower the conduction velocity of nerve. After treatment by Jinmaitong capsule, the scores of TCM symptoms and neurological function were obviously decreased, and the neurological symptoms and signs were improved. Furthermore, the abnormal parameters of nerve conduction velocity and sympathetic skin response test were also improved. JMT capsule can also reduce fasting and postprandial blood glucose, total cholesterol, triglyceride, whole blood viscosity and plasma viscosity, improve erythrocyte deformability, and reduce the activity of aldose reductase and the concentration of sorbitol, increase the activity of Na+/K+ -ATPase. The patients treated with Jinmaitong capsule had no definite adverse reactions during the medication. Conclusion & Significance: Chinese medicine Jinmaitong capsule is an effective and safe medicine for the treatment of DPN.


 

Grzegorz Onik

Medical University of Silesia in Katowice, Poland

Title: Treatment of diabetic foot ulcers with physical medicine modalities.
Speaker
Biography:

Grzegorz Onik is physiotherapist trying to promote application of physical medicine modalities
 
in internal diseases. He is a lecturer at Medical University of Silesia in Katowice in Department
 
of Physical Medicine.

 

Abstract:

Diabetic foot ulcers treatment requires multidisciplinary approach. To reduce the lower limbs amputations rate various procedures are applied. Physical medicine modalities may complement standard treatment. Variable magnetic fields, low-level laser therapy and local hyperbaric oxygen therapy are frequently applied modalities in Poland to promote diabetic foot ulcers. These procedures are proved to stimulate epithelization, new blood vessels creation and reduce pain. The study aims were assessment of rheological properties of blood in people with diabetic foot ulcers and the influence of local hyperbaric oxygen therapy on rheological properties of blood in people with diabetic foot ulcers.
Study included 36 people divided into two group. Study group constituted 16 people with diabetic foot ulcerations: 2 females and 14 males with mean age: 66,66±9,39 years. Control group constituted 20 healthy people: 14 females and 6 males with mean age: 52,6±7,24 years. In study group rheological properties of blood were assessed twice: before and after treatment with local hyperbaric oxygen therapy. In diabetic patients, in comparison with healthy subjects, increased blood and plasma viscosity were obtained. Erythrocytes’ aggregation parameters were altered also. Application of local hyperbaric oxygen therapy resulted in blood viscosity decrease at shear velocity equal 150 s-1. The influence of local hyperbaric oxygen therapy requires further research. However, obtained results may encourage for usage of this modality as wounds healing was enhanced.